These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 34393017)

  • 1. Pre-existing immunity to cytomegalovirus in macaques influences human CMV vaccine responses in preclinical models.
    Webster H; Valencia S; Kumar A; Chan C; Dennis M; Roark H; Woods A; John S; Carfi A; Permar SR
    Vaccine; 2021 Sep; 39(38):5358-5367. PubMed ID: 34393017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization.
    Nelson CS; Jenks JA; Pardi N; Goodwin M; Roark H; Edwards W; McLellan JS; Pollara J; Weissman D; Permar SR
    J Virol; 2020 Apr; 94(9):. PubMed ID: 32051265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralization of Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targeting Viral gH/gL/pUL128-131 Pentameric Complex.
    Ha S; Li F; Troutman MC; Freed DC; Tang A; Loughney JW; Wang D; Wang IM; Vlasak J; Nickle DC; Rustandi RR; Hamm M; DePhillips PA; Zhang N; McLellan JS; Zhu H; Adler SP; McVoy MA; An Z; Fu TM
    J Virol; 2017 Apr; 91(7):. PubMed ID: 28077654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of vaccination with rhesus CMV (RhCMV) soluble gB with a RhCMV replication-defective virus deleted for MHC class I immune evasion genes in a RhCMV challenge model.
    Valencia S; Gill RB; Dowdell KC; Wang Y; Hornung R; Bowman JJ; Lacayo JC; Cohen JI
    Vaccine; 2019 Jan; 37(2):333-342. PubMed ID: 30522906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody responses to rhesus cytomegalovirus glycoprotein B in naturally infected rhesus macaques.
    Yue Y; Zhou SS; Barry PA
    J Gen Virol; 2003 Dec; 84(Pt 12):3371-3379. PubMed ID: 14645918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses Than the gB/MF59 Vaccine.
    Hu X; Karthigeyan KP; Herbek S; Valencia SM; Jenks JA; Webster H; Miller IG; Connors M; Pollara J; Andy C; Gerber LM; Walter EB; Edwards KM; Bernstein DI; Hou J; Koch M; Panther L; Carfi A; Wu K; Permar SR
    J Infect Dis; 2024 Aug; 230(2):455-466. PubMed ID: 38324766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Horizontal Transmission of Cytomegalovirus in a Rhesus Model Despite High-Level, Vaccine-Elicited Neutralizing Antibody and T-Cell Responses.
    Li J; Wellnitz S; Chi XS; Yue Y; Schmidt KA; Nguyen N; Chen W; Yurgelonis I; Rojas E; Liu Y; Loschko J; Pollozi E; Matsuka YV; Needle E; Vidunas E; Donald RGK; Moran J; Jansen KU; Dormitzer PR; Barry PA; Yang X
    J Infect Dis; 2022 Sep; 226(4):585-594. PubMed ID: 35413121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralization of rhesus cytomegalovirus IL-10 reduces horizontal transmission and alters long-term immunity.
    Deere JD; Chang WLW; Villalobos A; Schmidt KA; Deshpande A; Castillo LD; Fike J; Walter MR; Barry PA; Hartigan-O'Connor DJ
    Proc Natl Acad Sci U S A; 2019 Jun; 116(26):13036-13041. PubMed ID: 31189602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice.
    Chiuppesi F; Nguyen J; Park S; Contreras H; Kha M; Meng Z; Kaltcheva T; Iniguez A; Martinez J; La Rosa C; Wussow F; Diamond DJ
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30045984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions.
    Nelson CS; Huffman T; Jenks JA; Cisneros de la Rosa E; Xie G; Vandergrift N; Pass RF; Pollara J; Permar SR
    Proc Natl Acad Sci U S A; 2018 Jun; 115(24):6267-6272. PubMed ID: 29712861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques.
    Wussow F; Yue Y; Martinez J; Deere JD; Longmate J; Herrmann A; Barry PA; Diamond DJ
    J Virol; 2013 Feb; 87(3):1322-32. PubMed ID: 23152525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and protective efficacy of DNA vaccines expressing rhesus cytomegalovirus glycoprotein B, phosphoprotein 65-2, and viral interleukin-10 in rhesus macaques.
    Yue Y; Kaur A; Eberhardt MK; Kassis N; Zhou SS; Tarantal AF; Barry PA
    J Virol; 2007 Feb; 81(3):1095-109. PubMed ID: 17108040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine-Derived Neutralizing Antibodies to the Human Cytomegalovirus gH/gL Pentamer Potently Block Primary Cytotrophoblast Infection.
    Chiuppesi F; Wussow F; Johnson E; Bian C; Zhuo M; Rajakumar A; Barry PA; Britt WJ; Chakraborty R; Diamond DJ
    J Virol; 2015 Dec; 89(23):11884-98. PubMed ID: 26378171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and Functional Characterization of a Novel Fc Gamma-Binding Glycoprotein in Rhesus Cytomegalovirus.
    Kolb P; Sijmons S; McArdle MR; Taher H; Womack J; Hughes C; Ventura A; Jarvis MA; Stahl-Hennig C; Hansen S; Picker LJ; Malouli D; Hengel H; Früh K
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30487278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrahost Dynamics of Human Cytomegalovirus Variants Acquired by Seronegative Glycoprotein B Vaccinees.
    Nelson CS; Vera Cruz D; Su M; Xie G; Vandergrift N; Pass RF; Forman M; Diener-West M; Koelle K; Arav-Boger R; Permar SR
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30518646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus.
    Fu TM; Wang D; Freed DC; Tang A; Li F; He X; Cole S; Dubey S; Finnefrock AC; ter Meulen J; Shiver JW; Casimiro DR
    Vaccine; 2012 Dec; 30(52):7469-74. PubMed ID: 23107592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenesis of Wild-Type-Like Rhesus Cytomegalovirus Strains following Oral Exposure of Immune-Competent Rhesus Macaques.
    Yue Y; Chang WLW; Li J; Nguyen N; Schmidt KA; Dormitzer PR; Yang X; Barry PA
    J Virol; 2022 Feb; 96(3):e0165321. PubMed ID: 34788083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.
    Schleiss MR; Berka U; Watson E; Aistleithner M; Kiefmann B; Mangeat B; Swanson EC; Gillis PA; Hernandez-Alvarado N; Fernández-Alarcón C; Zabeli JC; Pinschewer DD; Lilja AE; Schwendinger M; Guirakhoo F; Monath TP; Orlinger KK
    Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27795301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex.
    Wussow F; Chiuppesi F; Martinez J; Campo J; Johnson E; Flechsig C; Newell M; Tran E; Ortiz J; La Rosa C; Herrmann A; Longmate J; Chakraborty R; Barry PA; Diamond DJ
    PLoS Pathog; 2014 Nov; 10(11):e1004524. PubMed ID: 25412505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IgA binds to the AD-2 epitope of glycoprotein B and neutralizes human cytomegalovirus.
    Siddiqui S; Hackl S; Ghoddusi H; McIntosh MR; Gomes AC; Ho J; Reeves MB; McLean GR
    Immunology; 2021 Mar; 162(3):314-327. PubMed ID: 33283275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.